Mesoporous silica nanoparticles (MSNs) have emerged as promising drug carriers. Here we highlight some recent developments related to cell-specific targeting and delivery using MSNs. Some key requirements for carrier design are discussed from a biological perspective, including a suggested experimental work-flow for the evaluation of active cell-specific targeting of nanoparticles.
No takes yet. Share an insight, caveat, or question.
Rosenholm et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: